The Pension Fund Challenge—And Why Royalties Address It Defined benefit pension plans face a structural dilemma: actuarial assumptions of

What Are Indication-Specific Royalties? Indication-specific royalties are royalty financing or licensing arrangements where payments are tied only to sales of

The third week of January, recorded over $10 billion in confirmed and potential transaction value across 30+ biotech, pharmaceutical, and

The pharmaceutical royalty market has deployed over $29 billion since 2020 into patent-protected assets—yet systematically ignores a parallel universe

BCM Europe AG occupies an unusual position in the pharmaceutical financing landscape. The Zug-based investment company has quietly assembled control

Biotechnology startups often promise to "drug the undruggable," but few have embraced that challenge as boldly as Proxima Biosciences.

Patent expiration is the single largest value driver in pharmaceutical royalty valuation, yet most market participants use oversimplified assumptions. Rigorous

The GTN Landscape: A $356 Billion Problem Enters a New Era "Gross-to-net" (GTN) refers to the difference between

In Silico Medical Device Regulation Reaches Global Inflection Point The regulatory landscape for computational modeling in medical device development has

The second week of 2026—dominated by the 44th Annual J.P. Morgan Healthcare Conference in San Francisco—delivered over $12 billion in announced transaction value despite the conspicuous absence of any transformational M&A